Clinical Trials · NCT07220759
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 330
- Start date
- Nov 2025
- Locations
- 67 sites, 11 countries
- Primary endpoint
- Relative change in body weight